[go: up one dir, main page]

MX2019012058A - Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas. - Google Patents

Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas.

Info

Publication number
MX2019012058A
MX2019012058A MX2019012058A MX2019012058A MX2019012058A MX 2019012058 A MX2019012058 A MX 2019012058A MX 2019012058 A MX2019012058 A MX 2019012058A MX 2019012058 A MX2019012058 A MX 2019012058A MX 2019012058 A MX2019012058 A MX 2019012058A
Authority
MX
Mexico
Prior art keywords
potency
assay
receptor
nanomedicines
measure
Prior art date
Application number
MX2019012058A
Other languages
English (en)
Inventor
Santamaria Pedro
Original Assignee
Uti Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Lp filed Critical Uti Lp
Publication of MX2019012058A publication Critical patent/MX2019012058A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)

Abstract

En este documento, se describe una célula aislada que comprende un receptor de células T recombinante (TCR) y un marcador dependiente de la vía TCR, en donde el receptor de células T recombinante es específico para un antígeno relevante para la enfermedad unido a una molécula de MHC. También se describen métodos de uso para una célula aislada, como un ensayo para determinar la función o la potencia de un complejo mayor de histocompatibilidad de un péptido (pMHC), acoplado a una nanopartícula (pMHC-NP), que se puede usar como medicamento para tratar una enfermedad autoinmune o cáncer.
MX2019012058A 2017-04-07 2018-04-05 Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas. MX2019012058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483298P 2017-04-07 2017-04-07
PCT/IB2018/000510 WO2018185564A2 (en) 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines

Publications (1)

Publication Number Publication Date
MX2019012058A true MX2019012058A (es) 2019-11-11

Family

ID=63713282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012058A MX2019012058A (es) 2017-04-07 2018-04-05 Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas.

Country Status (14)

Country Link
US (2) US20200057048A1 (es)
EP (1) EP3607058A4 (es)
JP (2) JP2020516594A (es)
KR (1) KR20200004807A (es)
CN (1) CN110945120B (es)
AU (1) AU2018248961B2 (es)
BR (1) BR112019021022A2 (es)
CA (1) CA3059016A1 (es)
CO (1) CO2019011018A2 (es)
IL (1) IL269846A (es)
MX (1) MX2019012058A (es)
RU (1) RU2019135533A (es)
SG (1) SG11201909290TA (es)
WO (1) WO2018185564A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
DK3065771T3 (da) 2013-11-04 2019-06-11 Uti Lp Fremgangsmåder og sammensætninger til vedvarende immunterapi
KR102859521B1 (ko) 2015-05-06 2025-09-12 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
JP7174144B2 (ja) * 2018-08-06 2022-11-17 メディジーン イミュノテラピーズ ゲーエムベーハー Ｈａ－１特異的ｔ細胞受容体およびその使用
JP7731805B2 (ja) * 2019-05-23 2025-09-01 ユーティアイ・リミテッド・パートナーシップ 肝疾患の治療方法
KR20220150276A (ko) * 2020-01-11 2022-11-10 시벡 바이오테크놀로지스, 엘엘씨 진핵생물로의 진핵생물-번역가능한 mRNA의 생산 및 전달을 위한 미생물 시스템
CA3176401A1 (en) * 2020-04-21 2021-10-28 Wen Zhang Methods and systems for analysis of receptor interaction
AU2021210629A1 (en) * 2020-05-06 2022-12-08 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) * 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CA3232037A1 (en) * 2021-09-21 2023-03-30 Monash University Methods of treatment
CN113960003B (zh) * 2021-10-20 2023-10-24 吉林大学 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器
US11873507B2 (en) 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
EP4249062A1 (en) * 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
CN115125205A (zh) * 2022-06-14 2022-09-30 中国医学科学院生物医学工程研究所 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法
WO2024248042A1 (ja) * 2023-05-29 2024-12-05 国立大学法人 東京大学 ＭｕＳＫを標的とする新規化合物及びその用途
TW202530251A (zh) * 2023-09-22 2025-08-01 德國符茲堡大學 ＭＨＣ Ｉｂ媒介之水通道蛋白４（ＡＱＰ４）特異性免疫抑制作為用於ＮＭＯ之新穎治療

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
JP2002513765A (ja) 1998-05-07 2002-05-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答の調節における無視された標的組織抗原の使用
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
EP1373536B9 (en) 2001-03-13 2009-09-02 Novartis AG Lentiviral packaging constructs
GB0417954D0 (en) * 2004-08-12 2004-09-15 Avidex Ltd Cellulat TCR ligand assay method
EP3269384A1 (en) * 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
AU2009315230A1 (en) 2008-11-12 2010-05-20 The Brigham And Women's Hospital, Inc. Diagnosis of multiple sclerosis
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
EP2621523B1 (en) 2010-09-29 2017-08-09 UTI Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US8809057B2 (en) * 2012-01-04 2014-08-19 Raytheon Bbn Technologies Corp. Methods of evaluating gene expression levels
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP6014440B2 (ja) 2012-09-26 2016-10-25 日立オートモティブシステムズ株式会社 移動物体認識装置
DK3065771T3 (da) 2013-11-04 2019-06-11 Uti Lp Fremgangsmåder og sammensætninger til vedvarende immunterapi
US20160169869A1 (en) * 2014-11-20 2016-06-16 Promega Corporation Systems and methods for assessing modulators of immune checkpoints
CA2969056C (en) 2014-12-19 2023-09-05 Eth Zurich Chimeric antigen receptors and methods of use
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
BR112017020750A2 (pt) * 2015-03-27 2018-06-26 Harvard College células t modificadas e métodos de produção e utilização das mesmas
KR102859521B1 (ko) * 2015-05-06 2025-09-12 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
CA2987857A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
MA44907A (fr) * 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation

Also Published As

Publication number Publication date
JP2020516594A (ja) 2020-06-11
SG11201909290TA (en) 2019-11-28
US20240201171A1 (en) 2024-06-20
AU2018248961B2 (en) 2024-06-20
AU2018248961A1 (en) 2019-10-31
JP2024073459A (ja) 2024-05-29
EP3607058A4 (en) 2020-12-16
CN110945120A (zh) 2020-03-31
BR112019021022A2 (pt) 2020-06-09
KR20200004807A (ko) 2020-01-14
WO2018185564A3 (en) 2019-01-03
WO2018185564A2 (en) 2018-10-11
EP3607058A2 (en) 2020-02-12
CO2019011018A2 (es) 2019-10-21
CN110945120B (zh) 2025-04-18
IL269846A (en) 2019-11-28
US20200057048A1 (en) 2020-02-20
CA3059016A1 (en) 2018-10-11
RU2019135533A (ru) 2021-05-07

Similar Documents

Publication Publication Date Title
MX2019012058A (es) Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas.
CL2020001989A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
CR20200287A (es) Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
PE20180695A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de prostata y otros tipos de cancer
BR112021019066A2 (pt) Receptores de células t para mage a4
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
PH12021553152A1 (en) Mage-a4 t cell receptors and methods of use thereof
MX390756B (es) Célula t asesina universal
CO2019008008A2 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
AR112902A1 (es) Receptores de células t restringidas a hla de clase ii contra ras mutado
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
EP4219552A3 (en) Il-11r binding proteins and uses thereof
MX2020002612A (es) Anticuerpos de la proteina de muerte celular programada 1.
CR20210068A (es) NUEVOS PÉPTIDOS Y ESTRUCTURAS DE SOPORTE PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CARCINOMA EPIDERMOIDE DE CABEZA Y CUELLO Y OTROS DE CÁNCER (Divisional 2019-0094)
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
PH12022551857A1 (en) Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
CO2019012071A2 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer
CO2020001141A2 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
CL2017002766A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cáncer
MX2022005570A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.
Cortinovis et al. Focus on Nivolumab in NSCLC
AR121812A2 (es) Péptido, vector de expresión, célula huésped, linfocito t activado, anticuerpo, receptor de células t, composición farmacéutica, kit y métodos relacionados
Chhaya Effects of Progesterone Receptor-B Ablation on Prepartum Remodeling of the Cervix
Liston Is foxp3 the master regulator of regulatory T cells?